| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,740 |
3,990 |
$205K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,447 |
3,550 |
$168K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,732 |
1,598 |
$117K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
5,061 |
4,363 |
$116K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,308 |
2,288 |
$87K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,736 |
1,598 |
$39K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
661 |
652 |
$33K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
631 |
315 |
$7K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
52 |
52 |
$5K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
109 |
100 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
94 |
87 |
$3K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
576 |
548 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
236 |
235 |
$1K |
| 99000 |
|
496 |
452 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
586 |
564 |
$1K |
| 0003A |
|
21 |
21 |
$975.22 |
| 0012A |
|
16 |
16 |
$750.88 |
| 0011A |
|
17 |
17 |
$707.09 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
13 |
13 |
$544.00 |
| 96127 |
|
297 |
287 |
$447.79 |
| S9083 |
Global fee urgent care centers |
21 |
18 |
$152.50 |
| 99072 |
|
2,198 |
1,941 |
$150.00 |
| 81002 |
|
65 |
60 |
$136.67 |
| 81025 |
|
16 |
15 |
$101.33 |
| 99441 |
|
12 |
12 |
$12.69 |
| 1036F |
|
67 |
62 |
$0.00 |
| 1125F |
|
71 |
67 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
782 |
676 |
$0.00 |
| 1111F |
|
1,215 |
1,061 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
542 |
471 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
190 |
174 |
$0.00 |
| 1126F |
|
132 |
112 |
$0.00 |
| G8419 |
Bmi documented outside normal parameters, no follow-up plan documented, no reason given |
15 |
14 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
660 |
562 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
138 |
122 |
$0.00 |
| 1159F |
|
240 |
199 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
780 |
672 |
$0.00 |
| 1160F |
|
238 |
197 |
$0.00 |
| 1124F |
|
17 |
17 |
$0.00 |
| G8731 |
Pain assessment using a standardized tool is documented as negative, no follow-up plan required |
89 |
77 |
$0.00 |